Anti-AAV Immunity Constrains Viral Reprogramming In Vivo
Pre-existing anti-AAV immunity is a major translational constraint for viral in vivo reprogramming programs; screening for neutralizing and capsid-binding antibodies before AAV dosing materially strengthens trial design and feasibility assessment.
In vivo tissue reprogramming applies transient expression of Yamanaka or related reprogramming factors in adult tissues to reverse cellular age marks and restore function — without fully dedifferentiating the cells.
In viral in vivo reprogramming programs that involve AAV vector dosing, the key translational constraint is pre-existing anti-AAV immunity. Some participants already have neutralizing and capsid-binding antibodies against AAV. For them, AAV vector dosing carries immune-mediated gene-therapy risk.
The Measure Anti-AAV Immunity node sits inside Operating Trials — clinical-trial infrastructure covering inclusion-criteria methodology, statistical methods, and regulatory support. Its job: measure neutralizing and capsid-binding antibody levels before AAV vector dosing and exclude participants whose immune response would likely compromise therapy.
This screening materially strengthens trial design and clinical feasibility assessment. Our confidence in this link is high — anti-AAV immunity is one of the major translational constraints for viral in vivo reprogramming programs.
Next: determine which viral in vivo reprogramming programs already screen for anti-AAV antibodies and how participant selection by immune profile works in practice. We do not have these data yet.
The anti-AAV immunity → in vivo reprogramming edge is rated high-confidence in the system and directly constrains the feasibility of the field's leading programs, yet the operational specifics (which programs screen, what thresholds, serotype-geography mapping) remain unmapped — making it a strong candidate for a route-gap dispatch.